Navigation Links
Vion Pharmaceuticals to Present Data on Onrigin(TM)at the ASCO(R) Annual Meeting
Date:5/29/2009

NEW HAVEN, Conn., May 29 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that an analysis of clinical data of its lead anticancer agent Onrigin (laromustine) Injection in acute myeloid leukemia (AML) would be presented in a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida.

The poster (Abstract #7050) entitled "Comorbidity Description Using the Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) in Elderly de novo Poor Risk AML Patients Treated with Laromustine" will be presented at the Orange County Convention Center, Level 2, West Hall C, Board #M4 from 8:00 a.m. to 12:00 p.m. on Saturday, May 30, 2009. A copy of the poster will be available on Vion Pharmaceuticals' website, www.vionpharm.com, on May 30, 2009 at 8:00 a.m. Eastern Time.

In addition, the Company announced that additional data on Onrigin would be presented in a poster from an investigator-sponsored trial of Onrigin in combination with cytarabine in elderly patients with previously untreated AML. The trial is sponsored by the Weill-Cornell Medical College. The poster (Abstract #7054) entitled "Phase I Trial of Laromustine in Combination with Infusional Ara-C in Elderly Patients Over Age 60 with Newly Diagnosed AML or High-Grade MDS" will be presented at the Orange County Convention Center, Level 2, West Hall C, Board #M10 from 8:00 a.m. to 12:00 p.m. on Saturday, May 30, 2009.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative oncology therapeutics. Vion has two agents in clinical trials, Onrigin (laromustine) Injection and Triapine(R). The Company has an NDA under review with the FDA fo
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009
2. American Academy of Dermatology Recognizes Merz Pharmaceuticals
3. Transcept Pharmaceuticals to Present at Needham Life Sciences Conference on June 10, 2009
4. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
5. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
6. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
7. Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)
8. MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
9. Agios Pharmaceuticals founders author Science review on cancer metabolism
10. Transcept Pharmaceuticals Presents Data from Studies of Two Product Candidates at Annual Meeting of the American Psychiatric Association
11. Celator(R) Pharmaceuticals Initiates Research Agreement With Cephalon, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... East Liverpool, OH (PRWEB) May 22, 2015 ... today announced that Kyle Johnson, the health system’s Chief ... pursue other interests. Johnson has served as the company ... announced Wesley West will be joining the health system ... operations on an interim basis, while the Board of ...
(Date:5/22/2015)... Halifax, NS (PRWEB) May 22, 2015 ... into a sale agreement with US-based health brand Nature’s ... Ascenta Skin brand. Retention of Ascenta Skin is an ... St-Onge is excited about this opportunity to further develop ... industry. , Ascenta Skin is a breakthrough, anti-aging ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Combination ... treatment option for chronic obstructive pulmonary disorder (COPD) ... plc and AstraZeneca plc as well as Germany’s ... share and position. But will market payers, clinicians ... already well-entrenched products to completely new ones? , ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 “It’s ... MS/CCC, SLP, RAC-CT, CHHRP-QT, Vice President of Clinical ... very important ‘language’ that impacts how care is ... leader in long term care reimbursement, operations and ... programs and talent management, launches a new series ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming June Events 2Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Ascenta Skin President Announces Plans to Grow Brand 2Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3
... of Cincinnati (UC) researcher will receive $2.5 million over ... (NIDA) to support his work on a potential immunotherapy ... in the psychiatry and behavioral neuroscience department, is one ... Awards for Innovative Medication Development Research. Award winners receive ...
... targeted therapies can reduce tumors rapidly. However, not all ... do often develop resistance over time. Looking for a ... Fox Chase Cancer Center hypothesized that hitting already weakened ... thembut only if it was the right second agent. ...
... be improved with training and the improvement is marked ... University study. A research team led by ... of the brain that controls impulsive behavior and the ... findings could have a significant impact on the diagnosis ...
... By Steven Reinberg HealthDay Reporter , ... finds it,s safe to take the blood thinner Plavix ... that said the combination compromised Plavix,s effectiveness. "We ... and proton-pump inhibitors," said lead researcher Dr. Mette Charlot ...
... tenth anniversary of the Jackson Heart Study (JHS) will ... JHS is the largest study in history to investigate ... lung disease, stroke, diabetes, and other important diseases in ... among African-Americans than among whites in the United States. ...
... CHAPEL HILL, N.C. Scientists from University of North Carolina ... Inc. announced today findings from a large clinical study ... the worsening of osteoarthritis. The study, which was ... with X-ray evidence of knee osteoarthritis who inherited a ...
Cached Medicine News:Health News:Researcher wins $2.5 million award from National Institute on Drug Abuse 2Health News:'Synthetic lethality' strategy improves molecularly targeted cancer therapy 2Health News:'Synthetic lethality' strategy improves molecularly targeted cancer therapy 3Health News:Queen's University researchers locate impulse control center in brain 2Health News:Plavix, Heartburn Drug Safe to Take Together: Study 2Health News:NIH celebrates 10 years of research into health disparities 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 2Health News:UNC researchers identify genetic patterns that may predict osteoarthritis 3
(Date:5/22/2015)... 2015 Richmond Pharmacology is ... with a worldwide reputation for excellence in clinical ... in peer reviewed medical journals. Its officers are ... in discussions about rules for transparency and publication ... http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is conducted ...
(Date:5/21/2015)... Research and Markets ... of the "North American Joint Reconstruction ... Elbow Replacement, Hip Replacement, Knee Replacement, Shoulder ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... at $4,470.9 million in 2014 and is ...
(Date:5/21/2015)... May 21, 2015 Research ... addition of the "Market Assessment of Respiratory ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... respiratory imaging diagnostics market in the ... . The service provides detailed analysis of ...
Breaking Medicine Technology:North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... Medical, Inc. (OTCBB: HASC), www.mysouthernmed.com , a managed ... Mississippi, announced the launch of a newly redesigned  web ... Vans of America ( www.WCvans.com ). ... more customer friendly.   MobilityFreedom.com now provides an ...
... BRISBANE, Calif., July 18, 2011 SARcode Bioscience, ... completion of a $44 million Series B private ... Sofinnova Ventures and was augmented by the additional ... Partners and Clarus Venture Partners. ...
Cached Medicine Technology:HASCO Medical Announces New Redesigned Websites for Mobility Freedom and Wheelchair Vans of America 2SARcode Bioscience Completes $44 Million Series B Financing 2SARcode Bioscience Completes $44 Million Series B Financing 3SARcode Bioscience Completes $44 Million Series B Financing 4
... respiration and ventilation., ,The Capnomac Ultima is ... monitors available. The Capnomac Ultima is available in ... measure the essential airway gas parameters, CO 2 ... O easily and reliability. The Capnomac Ultima also ...
Adhesive discs sold on rolls of 100, 250, or 1000 each. Manufactured from non-latex medical grade adhesives & material. One size fits all chest pieces....
For accurately monitoring core temperature and heart and breath sounds as well as for gastric suctioning....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: